Publications by authors named "Yurii Ostapenko"
Article Synopsis
- - The study investigates the effectiveness of amivantamab plus lazertinib compared to osimertinib in treating patients with advanced non-small-cell lung cancer (NSCLC) caused by specific genetic mutations.
- - Results showed that patients receiving the amivantamab-lazertinib treatment had a significantly longer progression-free survival (23.7 months) than those on osimertinib (16.6 months), and the response rate was similar among both groups.
- - Side effects primarily related to treatment were noted, but the overall survival analysis indicated a potential benefit for amivantamab-lazertinib over osimertinib, with fewer serious complications leading to treatment discontinuation.
Purpose: In the phase III HIMALAYA study (ClinicalTrials.gov identifier: NCT03298451) in unresectable hepatocellular carcinoma (uHCC), the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen significantly improved overall survival versus sorafenib, and durvalumab monotherapy was noninferior to sorafenib. Patient-reported outcomes (PROs), a secondary outcome from HIMALAYA, are reported here.
View Article and Find Full Text PDFArticle Synopsis
- The HIMALAYA study compared the effectiveness of the STRIDE regimen (tremelimumab plus durvalumab) and durvalumab alone against sorafenib for treating unresectable hepatocellular carcinoma (HCC), a difficult-to-treat liver cancer.
- Results showed that participants receiving STRIDE lived longer and had a lower risk of worsening quality of life compared to those taking sorafenib, while those on durvalumab alone had similar survival to the sorafenib group.
- The findings indicate that STRIDE is a more effective treatment option than sorafenib for patients with unresectable HCC, with manageable side effects associated with the immunotherapy drugs.
Unlabelled: For the last three decades, the world surgical community successfully adopted different surgical strategies for colorectal cancer (CRC) patients with liver metastases (LM), however, we are still seeing the evolution of treatment guidelines. The purpose of the study was to analyze a 20-year evolution of CRC patients with LM being treated in a specialized state Ukrainian oncological center.
Materials And Methods: The retrospective analysis of 1118 CRC patient cases using prospectively collected patient data from the National Cancer Institute registry.